Rachel Klemovitch, Assistant Editor01.25.24
Icotec ag, a leading company in spinal tumor implants has established a strategic partnership with global healthcare venture capital firm, MVM Partners. The partnership helps icotec to commercialize its BlackArmor Carbon/PEEK products.
"We are thrilled to partner with MVM, whose deep understanding of the healthcare landscape aligns seamlessly with our vision for the future," said icotec CEO Roger Stadler. "This partnership marks a pivotal moment for icotec, supporting us to advance our mission of improving patient outcomes by offering a convincing alternative to the 100-year-old material technology of metal implants."
Icotec’s BlackArmor products received FDA clearance in 2019, and since then have been adopted into designated US cancer centers. MVM’s investment enables icotec to strengthen and grow its research and development capabilities and expand its portfolio into spinal infection and osteoporosis categories.
MVM partner Thomas Casdagli commented, "We are excited to support icotec in its mission to revolutionize the spinal implant industry. icotec's BlackArmor Carbon/PEEK implants represent a huge step forward in the treatment of complex spine disease. For the first time clinicians have the choice to be able to accurately visualize and treat patients after surgery without the artifacts and limitations of traditional metal implants. We see this as a big step forward for patient care. We look forward to working closely with the icotec team to drive continued success and growth."
"We are thrilled to partner with MVM, whose deep understanding of the healthcare landscape aligns seamlessly with our vision for the future," said icotec CEO Roger Stadler. "This partnership marks a pivotal moment for icotec, supporting us to advance our mission of improving patient outcomes by offering a convincing alternative to the 100-year-old material technology of metal implants."
Icotec’s BlackArmor products received FDA clearance in 2019, and since then have been adopted into designated US cancer centers. MVM’s investment enables icotec to strengthen and grow its research and development capabilities and expand its portfolio into spinal infection and osteoporosis categories.
MVM partner Thomas Casdagli commented, "We are excited to support icotec in its mission to revolutionize the spinal implant industry. icotec's BlackArmor Carbon/PEEK implants represent a huge step forward in the treatment of complex spine disease. For the first time clinicians have the choice to be able to accurately visualize and treat patients after surgery without the artifacts and limitations of traditional metal implants. We see this as a big step forward for patient care. We look forward to working closely with the icotec team to drive continued success and growth."